Cardiovascular risk prevention in peripheral artery disease

Area of Science:

• Cardiology
• Vascular Medicine
• Pharmacology

Background:

• Peripheral arterial disease (PAD) patients have a significantly increased risk of stroke, myocardial infarction, and cardiovascular death.
• PAD is associated with a six-fold higher mortality rate from cardiovascular causes compared to the general population.

Purpose of the Study:

• To summarize evidence-based cardiovascular protection strategies for patients with peripheral arterial disease.
• To highlight the combined effectiveness of antiplatelet agents, statins, and angiotensin-converting enzyme inhibitors in reducing cardiovascular events.

Main Methods:

• Review of available evidence supporting specific pharmacotherapies for cardiovascular protection in PAD.
• Analysis of the cumulative risk reduction achieved by combining multiple therapeutic interventions.

Main Results:

• Evidence supports the use of antiplatelet agents, statins, and angiotensin-converting enzyme inhibitors for cardiovascular protection in PAD.
• Combined therapy is projected to yield an approximately 80% cumulative relative risk reduction for cardiovascular events.
• Multidrug therapy, lifestyle changes, and revascularization can substantially decrease morbidity and mortality.

Conclusions:

• A combination of antiplatelet agents, statins, and ACE inhibitors is recommended for cardiovascular risk reduction in PAD.
• Aggressive management including pharmacotherapy, lifestyle modification, and revascularization is crucial for improving outcomes in PAD patients.